Press release
Scitara Corp. raises $15m in Series B Financing to disrupt the laboratory data integration market
Scitara Corp, a proven innovator in laboratory digital transformation, today announces the closing of its Series B round with an additional investment of $15m. Led by existing investor Northpond Ventures, with participation from Flybridge Capital and experienced financial advisors to the biopharma and life science tools industry, the funding will springboard Scitara’s ambitious growth plans for 2022 and beyond to solve the laboratory data integration challenge.Scitara’s growth has been fuelled by the introduction of its industry leading category Scientific Integration Platform™ SIP™, a cloud native infrastructure that allows scientific laboratories to realize the full benefits of digital transformation. The Scitara SIP dramatically accelerates science by facilitating a modern, fully connected laboratory with data standardization, data mobility, flexibility and adaptability to a dynamic laboratory ecosystem.
Commenting on the Series B funding, founder and CEO of Scitara, Ajit Nagral, said: “This significant investment underlines the value of our offer to the global scientific community. Since the start of the pandemic, the global spotlight on science has never been sharper. As life science and pharma industries come under monumental pressure to deliver breakthroughs at accelerated speeds, the importance of accurate data custodianship in real time has never been more critical. Science is looking to technology to help digitize its processes and unlock the full potential of its data.
“Scientists need timely and seamless access to cross-functional data to advance their science. Scitara SIP integrates scientific data across the enterprise, and in tandem with artificial intelligence (AI) and analytics tools, scientists are provided new insights to drive faster decision making, and information to help accelerate products to market. Consequently, the market demand for Scitara SIP has been unprecedented.
“Scitara SIP powered by our Digital Lab Exchange™ DLX™ platform brings a breakthrough level of laboratory automation, and is designed to fully comply with the most stringent requirements of regulated markets.”
Andrea Jackson, Northpond Ventures Director and Scitara Board Director added: “How scientific data flows in research and development is critical to accelerating life-saving therapies to market. Scitara’s platform enables seamless integration of data across lab workflows and operations. We are keenly supportive of Ajit and his team who are positioned to drive meaningful transformation of scientific data.”
Chip Hazard, General Partner at Flybridge commented on the deal: “With an impressive list of strategic partners that include leading instrument, informatics, and global service organizations, and a growing list of diverse customers, including some of the world’s largest pharmaceutical companies, vaccine manufacturers, and cutting-edge biotechnology players, Scitara is leading the next generation of digital transformation in the lab. This aligns perfectly with our portfolio of technology investments that are driving industry forward.”
Scitara will use the Series B funding to accelerate platform innovation, deliver customer-driven technology offerings, grow its partner ecosystem, and build a community of scientists, developers, and industry consultants to help address an ever-growing list of customer needs.
More information on the benefits of the Scitara SIP is outlined in the whitepaper, Building the interconnected laboratory: data mobility to support digital transformation.
The Scott Partnership
1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA
Lucy Shaw, lrs@scottpr.com
Scitara is a global provider of cloud-based, industry-specific platform and solutions for the life sciences industry. Based in Massachusetts, the Scitara leadership brings decades of experience in solving digital challenges for the scientific laboratory: Meet the Modern Lab™. For more information, please visit scitara.com.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Scitara Corp. raises $15m in Series B Financing to disrupt the laboratory data integration market here
News-ID: 2523263 • Views: …
More Releases from Scott PR
Cmed and Larix fully integrated into Aixial Group, the CRO solution of ALTEN Gro …
Following its acquisition of Larix in 2019 and Cmed Group in 2021, Aixial Group has become a leading mid-size, global CRO, with strong US and European presence and more than 1,000 employees.
With over 30 years' experience in successful project delivery, Aixial Group continues to grow with the full integration of Larix and Cmed enabling it to extend its expertise and offerings, with more options for biotech and pharma sponsors at…
Clinical trial platform provider encapsia welcomes new COO
Horsham, United Kingdom, 20th December 2022: Clinical trial management solutions provider, encapsia, has announced the appointment of Francis Destin as its new Chief Operating Officer. Francis brings more than 20 years of expertise to the role, specialising in the management of data-related projects in clinical trials and statistical analysis software. His adoption of a future-facing approach to clinical research supports encapsia's vision of transforming clinical trials for the benefit of…
Sepha's new EZ Blister+ enables 21 CFR Part 11 compliant micro-batches
Sepha, the Northern Ireland-based manufacturer of pharmaceutical packaging and equipment, has developed a new compact small-batch blister packaging machine with full traceability and electronic data storage capabilities. The EZ Blister+ meets increased demand for 21 CFR Part 11 compliant micro-batches throughout the blister production lifecycle, from R&D right through to commercial production. It will launch via a live webinar on 6th April (https://app.livestorm.co/sepha/digitalisation-of-low-volume-blister-packaging).
The EZ+ Blister answers calls from larger pharmaceutical…
Global Pharmaceutical Company proves validity of AI in life sciences through Pan …
A Senior Principal Data Scientist from a leading global pharmaceutical company showcased its success stories of using Pangaea Data’s novel artificial intelligence driven product, PIES (Pangaea’s Intelligence Extractor and Summarization).
The presentation took place at the Bio-IT World Conference and Expo on 21st September 2021 and demonstrated that PIES’s inherent Natural Language Generation (NLG) methods provide clinicians and researchers with the ability to generate clinical narratives automatically based on discrete…
More Releases for Scitara
Global Laboratory Informatics Market to Reach $8.5 Billion by 2032, Fueled by Di …
Complete Report: https://www.alliedmarketresearch.com/laboratory-informatics-market-A109163
The global laboratory informatics market, valued at $3.5 billion in 2022, is projected to surge to $8.5 billion by 2032, expanding at a CAGR of 9.2%. This remarkable growth is propelled by the increasing pace of R&D investments, the rise of digital transformation in laboratories, and the tightening of regulatory compliance standards.
Laboratory informatics refers to software and IT solutions that enable labs to manage data more efficiently, streamline…
Digital Transformation Market Global Size, Growth Factors, Top Leaders, Opportun …
The global Digital Transformation Market size is to grow from USD 695.5 billion in 2023 to USD 3,144.9 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 24.1% during the forecast period.
Download Report Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43010479
As per verticals, the healthcare, life sciences & pharmaceuticals segment is to grow at the highest CAGR during the forecast period.
The healthcare, life sciences & pharmaceuticals vertical is expected to grow at…
Digital Biomanufacturing Market 2024-2033: Latest Trends, Recent Developments, G …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Digital Biomanufacturing Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The digital biomanufacturing market size has grown rapidly in recent years. It…
Digital Transformation Market Outlook; Up-to-date Development Data, Trends & For …
According to a research report "Digital Transformation Market by Offering (Solutions & Services), Technology (Cloud Computing, Big Data & Analytics, Blockchain, Cybersecurity, AI), Business Function (Accounting & Finance, IT, HR), Vertical,& Region - Global Forecast to 2030" published by MarketsandMarkets, the global digital transformation market size is to grow from USD 695.5 billion in 2023 to USD 3,144.9 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 24.1%…
Digital Transformation Market Size, Share, Growth, Trends, Demand Analysis
The global Digital Transformation Market size is to grow from USD 695.5 billion in 2023 to USD 3,144.9 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 24.1% during the forecast period.
Download Report Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43010479
As per verticals, the healthcare, life sciences & pharmaceuticals segment is to grow at the highest CAGR during the forecast period.
The healthcare, life sciences & pharmaceuticals vertical is expected to grow at the…
Digital Lab Management System Market Global Demand, Forecast 2023-2029 | Deep Re …
The Digital Lab Management System market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status…